Our findings show that low DCLK1 expression correlated with high or low CD8 + T cells predicts better survival in colon and stomach cancer patients, suggesting DCLK1 has the potential to be an adjuvant target to promote sensitivity in immunotherapy-resistant patients. Here, CD8A is linked to gastric neoplasm.